Get to know our amazingly versatile and unique RVF® technology

Our Products in Action

Reveal Single Tests

FDA-approved, MedMira’s Reveal G4 provides instant HIV results.

Learn More >

Multiplo Multiplex Tests

MedMira’s Multiplo multiplex tests include combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis.

Learn More >

Miriad Research Tools

Miriad includes toolkits to develop new diagnostic tests and commercialized combination tests.

Learn More >

About MedMira

MedMira is dedicated to improving human health by providing the best in rapid diagnostics. Our patented Rapid Vertical Flow Technology™ delivers fast, accurate results for a range of applications—helping care providers and their patients know more, instantly.

July 14, 2022

MedMira Strengthens and Expands Board
Halifax, Nova Scotia, 14 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the
appointment of Ms. Pascale Nini to the Board of Directors.

June 6, 2022

MedMira Receives Patent for its Unique Quantitative Diagnostic System
Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt
of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system.

May 27, 2022

MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
Halifax, Nova Scotia, 27 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark.

May 20, 2022

VYRATM Product Line Update
Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRATM product line.

©2020 MedMira Inc. All Rights Reserved.

Follow us on